S1900A Phase II

Coordinating Group: SWOG

A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

Participants:
SWOG, CTSU (Supported by Alliance, CCTG, ECOG-ACRIN, and NRG)

Date Activated:
01/28/2019

Study Chairs:
J Riess, P Wheatley-Price (CCTG)

Statisticians:
M Redman, K Minichiello

Project Manager:
S Basse

Data Coordinators:
L Highleyman, L Everhart

SCHEMA



Objectives

To evaluate the overall response rate (confirmed and unconfirmed, complete and partial) associated with rucaparib in genomic LOH high and/or deleterious BRCA1/2 mutations within cohort 1: patients with squamous cell histology or mixed histology with a squamous component; and cohort 2: patients with non-squamous histology (adenocarcinoma, large cell, or NSCLC NOS).

To evaluate investigator assessed progression-free survival and overall survival associated with rucaparib within each cohort.

To evaluate duration of response among responders within each cohort.

To evaluate the frequency and severity of toxicities associated with rucaparib among all patients enrolled on the study (combining cohorts).

Patient Population

Patients must have been eligible for the screening study and must have been assigned to the S1900A sub-study based on biomarker eligibility defined as LOH high and/or deleterious BRCA1/2 mutation. Patients must have progressed following the most recent line of therapy. Patients must have measurable disease by CT or MRI. Patients must not have leptomeningeal disease, spinal cord compression, or brain metastases unless they meet the criteria in the protocol. Patients must not have EGFR sensitizing mutations, EGFR T790M mutations, ALK gene fusions, ROS1 gene rearrangements, or BRAF V600E mutations unless they have progressed following all standard of care targeted therapy.

Patients must not have had prior treatment with any PARP inhibitor. Patients must not have received any prior systemic therapy within 21 days prior to sub-study registration and must have recovered (≤ Grade 1) from any side effects of prior therapy. Patients must not have received any radiation therapy or had a major surgery within 14 days prior to sub-study registration. Patients must have fully recovered from the effects of prior surgery. Patients must not be planning to receive any concurrent therapy for cancer while receiving treatment on this study.

Patients must have a Zubrod performance status of 0-1 and adequate hematologic, hepatic, cardiac, and renal function. Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection. Patients with a known history of HIV seropositivity must have undetectable viral load, an adequate CD4 count, must not require prophylaxis for any opportunistic infections, and must not be newly diagnosed within 12 months prior to sub-study registration. Patients must be able to take oral medications.

Patients must agree to have blood specimens submitted for circulating tumor DNA. Patients must be offered participation in banking and in the correlative studies for collection and future use of specimens.

Stratification/Descriptive Factors

Patients will be stratified into two cohorts based on their histology.

Cohort 1:
Squamous: Patients with squamous cell lung cancer, including mixed histology with any squamous component.

Cohort 2:
Non-squamous: Patients with non-squamous cell lung cancer (adenocarcinoma, large cell, NSCLC NOS).

Accrual Goals

The accrual goal is 44 patients per cohort to achieve 40 eligible patients per cohort. An interim analysis will take place when 20 patients are evaluable for response.